Genrix Bio: The new drug application for Talikizumab injection has been accepted
I'm PortAI, I can summarize articles.
Genrix Bio announced that its Talizumab injection (GR1802) new drug application has been accepted by the National Medical Products Administration. This drug is used for the treatment of moderate to severe atopic dermatitis in adults and has achieved the primary endpoint in Phase III clinical trials. Talizumab is a recombinant fully human anti-IL-4Rα monoclonal antibody that can inhibit Th2-type inflammatory responses mediated by IL-4 or IL-13. The drug is also being developed for other indications
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments